These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27182243)

  • 21. Prevalence of hepatitis C viral infection among injecting drug users in a Saudi Arabian hospital: A point cross sectional survey.
    Alibrahim OA; Misau YA; Mohammed A; Faruk MB; Ss I
    J Public Health Afr; 2018 May; 9(1):726. PubMed ID: 30079162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for hepatitis C virus infection among injecting drug users in Sydney.
    van Beek I; Buckley R; Stewart M; MacDonald M; Kaldor J
    Genitourin Med; 1994 Oct; 70(5):321-4. PubMed ID: 8001943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiological aspects of HCV infection in non-injecting drug users in the Brazilian state of Pará, eastern Amazon.
    Oliveira-Filho AB; Sawada L; Pinto LC; Locks D; Bahia SL; Castro JA; Hermes RB; Brasil-Costa I; Amaral CE; Lemos JA
    Virol J; 2014 Feb; 11():38. PubMed ID: 24564954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HCV genotype analysis in HCV-HIV-co-infected Puerto Ricans who are injecting drug users: undetermined and mixed infections.
    Ríos-Olivares E; Yamamura Y; Gómez MA; Guzmán L; Rodríguez N; Fernández D; Hunter Mellado R
    Cell Mol Biol (Noisy-le-grand); 2001 Sep; 47(6):1017-24. PubMed ID: 11785651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.
    Maher L; Jalaludin B; Chant KG; Jayasuriya R; Sladden T; Kaldor JM; Sargent PL
    Addiction; 2006 Oct; 101(10):1499-508. PubMed ID: 16968352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Risk factors for hepatitis C among injecting drug users in Oslo].
    Dalgard O; Egeland A; Ervik R; Vilimas K; Skaug K; Steen TW
    Tidsskr Nor Laegeforen; 2009 Jan; 129(2):101-4. PubMed ID: 19151801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning.
    Wand H; Spiegelman D; Law M; Jalaludin B; Kaldor J; Maher L
    Addiction; 2009 Dec; 104(12):2049-56. PubMed ID: 19804463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving survey methods in sero-epidemiological studies of injecting drug users: a case example of two cross sectional surveys in Serbia and Montenegro.
    Judd A; Rhodes T; Johnston LG; Platt L; Andjelkovic V; Simić D; Mugosa B; Simić M; Zerjav S; Parry RP; Parry JV
    BMC Infect Dis; 2009 Feb; 9():14. PubMed ID: 19203380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations.
    Removille N; Origer A; Couffignal S; Vaillant M; Schmit JC; Lair ML
    BMC Public Health; 2011 May; 11():351. PubMed ID: 21595969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia.
    Maher L; Chant K; Jalaludin B; Sargent P
    J Gastroenterol Hepatol; 2004 Oct; 19(10):1114-20. PubMed ID: 15377287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology of hepatitis C virus infection & liver disease among injection drug users (IDUs) in Chennai, India.
    Mehta SH; Vogt SL; Srikrishnan AK; Vasudevan CK; Murugavel KG; Saravanan S; Anand S; Kumar MS; Ray SC; Celentano DD; Solomon S; Solomon SS
    Indian J Med Res; 2010 Dec; 132(6):706-14. PubMed ID: 21245619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV infection and risk, prevention, and testing behaviors among injecting drug users -- National HIV Behavioral Surveillance System, 20 U.S. cities, 2009.
    Broz D; Wejnert C; Pham HT; DiNenno E; Heffelfinger JD; Cribbin M; Krishna N; Teshale EH; Paz-Bailey G;
    MMWR Surveill Summ; 2014 Jul; 63(6):1-51. PubMed ID: 24990587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C genotype distribution and homology among geographically disparate injecting drug users in Afghanistan.
    Sanders-Buell E; Rutvisuttinunt W; Todd CS; Nasir A; Bradfield A; Lei E; Poltavee K; Savadsuk H; Kim JH; Scott PT; de Souza M; Tovanabutra S
    J Med Virol; 2013 Jul; 85(7):1170-9. PubMed ID: 23918535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
    Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
    BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection.
    Hsieh MH; Tsai JJ; Hsieh MY; Huang CF; Yeh ML; Yang JF; Chang K; Lin WR; Lin CY; Chen TC; Huang JF; Dai CY; Yu ML; Chuang WL
    PLoS One; 2014; 9(4):e94791. PubMed ID: 24722534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phylogenetic analysis of hepatitis C virus strains and risk factors associated with infection and viral subtypes among Iranian patients.
    Salehi Moghadam F; Mohebbi SR; Hosseini SM; Romani S; Mirtalebi H; Azimzadeh P; Damavand B; Naghoosi H; Khanyaghma M; Sanati A; Zali MR
    J Med Virol; 2014 Aug; 86(8):1342-9. PubMed ID: 24838700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High dead-space syringes and the risk of HIV and HCV infection among injecting drug users.
    Zule WA; Bobashev G
    Drug Alcohol Depend; 2009 Mar; 100(3):204-13. PubMed ID: 19004579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users.
    Garfein RS; Doherty MC; Monterroso ER; Thomas DL; Nelson KE; Vlahov D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998; 18 Suppl 1():S11-9. PubMed ID: 9663618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of hepatitis C virus infection in injecting and noninjecting drug users receiving opioid substitution therapy.
    Wang CW; Chuang HY; Chiang HC; Huang PC; Yu ML; Dai CY
    J Chin Med Assoc; 2020 May; 83(5):454-460. PubMed ID: 32358454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular epidemiologic analysis of hepatitis C virus infection in injecting drug users with acute hepatitis C in Japan.
    Satoh Y; Hino K; Kato T; Mizokami M; Yamashita S; Nakamura H; Okita K
    J Gastroenterol Hepatol; 2004 Nov; 19(11):1305-11. PubMed ID: 15482539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.